Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of ReCOV, a Vaccine for COVID-19, in Healthy Adult Subjects

NCT04818801 is registered in ClinicalTrials.gov with Jiangsu Rec-Biotechnology Co., Ltd. as lead sponsor.

NCT NCT04818801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04818801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of ReCOV, a Vaccine for COVID-19, in Healthy Adult Subjects
Lead sponsor
Jiangsu Rec-Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2021
Completion date
May 5, 2022
Enrollment
100 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid19